\nSymbol: ANCN
\nDescription: They are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard treatment for early-stage bladder cancer, which is one of the most prevalent forms of cancer. Their ordinary shares are listed on the Tel Aviv Stock Exchange Ltd., or the TASE, under the symbol “ANCN”.
\nShares: 2.4 million ADSs
\nPrice Range: $14.55-$14.55
\nTrade Date: 2\/12
\nUnderwriter(s): Oppenheimer & Co.
\nCo-Manager(s): Ladenburg Thalmann
\nTerms Added: 1-31-19<\/p>\n
Link to Prospectus<\/strong><\/a><\/p>\n Link to Retail Roadshow<\/strong><\/a><\/p>\n Business (in their words) :<\/strong>We have discovered and are developing a biologic agent called inodiftagene vixteplasmid, or inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in efficacy and problematic in toxicity. Bladder cancer is a disease that typically causes symptoms early in its course and consequently presents the patient and the treating physician with an opportunity to gain control of the malignancy. However, the limitations of existing therapies, developed in the 1970s, often result in a prolonged series of unsuccessful treatments that can end in the radical removal of the bladder. Insider Buying:\u00a0<\/strong>Certain of their existing shareholders and\/or certain of their affiliates have indicated an interest in purchasing up to an aggregate of\u2009 $17.5\u00a0million of the ADSs<\/strong> in this offering at the initial public offering price.<\/p>\n \u00a0IPO Boutiuqe Color, Commentary & Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n![\"\"](\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2019\/02\/Screen-Shot-2019-02-08-at-9.46.44-PM-300x164.png\")
<\/a><\/p>\n